Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tanner

Showing results (631-640 of 855) with videos related to

Pageof 86
Sort By:
Cellular and Molecular Life Sciences : CMLS|February 27, 2010
A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levelsTamzin M Tanner, Sarah Denayer, Bart Geverts, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 25, 2007
Bowel movement frequency in late-life and incidental Lewy bodiesRobert D Abbott, G Webster Ross, Helen Petrovitch, et al.
The Journal of Pediatrics|May 23, 2007
Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intoleranceLaura M Tanner, Kirsti Näntö-Salonen, Harri Niinikoski, et al.
Journal of Clinical Lipidology|July 19, 2020
Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) studyRikki M Tanner, Lisandro D Colantonio, Meredith L Kilgore, et al.
Vaccine|February 1, 1994
A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and designP L Alonso, M Tanner, T Smith, et al.
The Lancet. Neurology|October 18, 2025
Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunitiesE Ray Dorsey, Briana R De Miranda, Sarrah Hussain, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.
Parkinsonism & Related Disorders|June 5, 2012
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variantsChaodong Wang, Yanning Cai, Zheng Zheng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, et al.
Optics Express|August 10, 2017
Time-resolved spectroscopy at 19,000 lines per second using a CMOS SPAD line array enables advanced biophotonics applicationsA Kufcsák, A Erdogan, R Walker, et al.
Pageof 86

Showing results (631-640 of 855) with videos related to

Sort By:
Pageof 86
Cellular and Molecular Life Sciences : CMLS|February 27, 2010
A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levelsTamzin M Tanner, Sarah Denayer, Bart Geverts, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 25, 2007
Bowel movement frequency in late-life and incidental Lewy bodiesRobert D Abbott, G Webster Ross, Helen Petrovitch, et al.
The Journal of Pediatrics|May 23, 2007
Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intoleranceLaura M Tanner, Kirsti Näntö-Salonen, Harri Niinikoski, et al.
Journal of Clinical Lipidology|July 19, 2020
Low-density lipoprotein cholesterol levels among individuals experiencing statin-associated symptoms: Data from the REasons for Geographic And Racial Differences in Stroke (REGARDS) studyRikki M Tanner, Lisandro D Colantonio, Meredith L Kilgore, et al.
Vaccine|February 1, 1994
A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and designP L Alonso, M Tanner, T Smith, et al.
The Lancet. Neurology|October 18, 2025
Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunitiesE Ray Dorsey, Briana R De Miranda, Sarrah Hussain, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive DyskinesiaStephen R Marder, Carlos Singer, Jean-Pierre Lindenmayer, et al.
Parkinsonism & Related Disorders|June 5, 2012
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variantsChaodong Wang, Yanning Cai, Zheng Zheng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 24, 2017
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, et al.
Optics Express|August 10, 2017
Time-resolved spectroscopy at 19,000 lines per second using a CMOS SPAD line array enables advanced biophotonics applicationsA Kufcsák, A Erdogan, R Walker, et al.
Pageof 86